Randomized, multicenter, open label study to compare the efficacy and tolerability of pegylated interferon-alpha-2a 8PEG-IFN) to "low dose" interferon-alpha-2a in patients with malignant melanoma in stages IIA (T3a) - IIIB (AJCC2002)
Sonstige